RESEARCH PROFILEClinical neuroscience, neuropsychopharmacology, cognitive neuroscience, psychosis, prodromal psychosis, affective disorders, psychopathology, neuroimaging, fMRI, EEG, resting-state, connectivity, computational neuroscience, biological psychiatry, biological marker.
BACKGROUNDDr. sc. nat. André Schmidt studied neuroscience at the ETH in Zurich. He completed his Ph.D. at the University Hospital of Psychiatry in Zurich working on electro-pharmacological models of psychosis with the aim to study pathophysiological mechanisms of specific symptom formation, in particular of cognitive impairments. Currently, André Schmidt works as a post-doc at the University Hospital of Psychiatry in Basel with a research focus on sophisticated connectivity analyses of resting-state and functional imaging data implicated in diverse psychiatric diseases.
CURRENT RESEARCH PROJECTSMultimodal imaging of the psychosis high-risk state. In different working projects, we try to find robust neuronal correlates underlying the onset of psychosis by using structural and functional magnetic resonance imaging measurements and computational modeling approaches during a variety of cognitive and emotional paradigms.
Resting-state fMRI analysis. I am working in different projects evaluating regional brain interactions during rest, i.e., without any task. In particular, we study how resting-state brain connectivity changes after pharmacological manipulations and physical training, as well as in different psychiatric diseases.
The neurobiology of drug addiction. In these research projects, we investigate how neuronal structures, functional brain activity and behavior are changed as a result of drug consumption.
Schmidt A, Cappucciati M, Radua J, Rutigliano G, Rocchetti M, Dell’Osso L, Politi P, Borgwardt S, Reilly T, Valmaggia L, McGuire P, Fusar-Poli (2017). Improving prognostic accuracy in subjects at clinical high risk for psychosis: systematic review of predictive models and meta-analytical sequential testing simulation. Schizophrenia Bulletin, 43(2):375-388.
Schmidt A, Crossley NA, Harrisberger F, Smieskova R, Lenz C, Riecher-Rössler A, Lang UE, McGuire P, Fusar-Poli P, Borgwardt S (2016). Structural network disorganization in subjects at clinical high risk for Psychosis. Schizophrenia Bulletin, 43(3):583-591.
Radua J, Schmidt A, Borgwardt S, Heinz A, Schlagenhauf F, Mcguire P, Fusar-Poli P (2015). Ventral striatal activation during reward processing in psychosis: A neurofunctional meta-analysis. JAMA Psychiatry, 72(12):1243-1251.
Schmidt A, Walter M, Gerber H, Seifritz E, Brenneisen R, Wiesbeck G, Riecher-Rössler A, Lang UE, Borgwardt S (2015). Normalising effect of heroin maintenance treatment on stress-induced brain connectivity. Brain, 138(Pt 1):217-228.
Schmidt A, Borgwardt S, Gerber H, Wiesbeck G, Schmid O, Riecher-Rössler A, Smieskova R, Lang UE, Walter M (2014). Acute effects of heroin on negative emotional processing: relation of amygdala activity and stress-related responses. Biological Psychiatry, 76(4):289-296.
Schmidt, A, Smieskova R, Aston, J, Simon A, Allen P, Fusar-Poli P, McGuire PK, Riecher-Rössler A, Stephan KE, Borgwardt S (2013). Brain connectivity abnormalities predating the onset of psychosis: correlation with the effect of medication. JAMA Psychiatry, 70(9):903-912.
Kometer M, Schmidt A, Jäncke L, Vollenweider FX (2013). Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. Journal of Neuroscience, 33(25):10544-10551.
Schmidt A, Diaconescu AO, Kometer M, Friston KJ, Stephan KE, Seifritz E, Vollenweider FX (2013). Modeling Ketamine Effects on Synaptic Plasticity During the Mismatch Negativity. Cerebral Cortex, 23(10):2394-2406.
Kometer M, Schmidt A, Bachmann R, Vollenweider FX (2012). Psilocybin biases facial recognition, goal-directed behavior, and mood state towards positive relative to negative emotions through different serotonergic subreceptors. Biological Psychiatry, 72(11):898-906.
Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, Vollenweider FX (2012). Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. Neuropsychopharmacology 37:865-75.
Schmidt A, Kometer M, Bachmann R, Seifritz E, Vollenweider FX (2012). The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology 2013 Jan;225(1):227-39. doi: 10.1007/s00213-012-2811-0. Epub 2012 Jul 27.
Borgwardt S, Schmidt A (2012). Molecular Bases Of Antipsychotic Drugs: The Contribution Of Neurosciences. Curr Med Chem 2013;20(3):311.
Smieskova R, Marmy J, Schmidt A, Bendfeldt K, Riecher-Rössler A, Walter M, Lang UE, Borgwardt S (2012). Do subjects at clinical high risk for psychosis differ from those with a genetic high risk? – A systematic review of structural and functional brain abnormalities.
Curr Med Chem, 2013;20(3):467-81.